文献速递肿瘤 PET/CT核素与放射性配体治疗

评估134Ce/134La作为225Ac α-放射治疗药物的PET成像诊疗对

Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac α-Radiotherapeutics.
PubMed 文献 · J Nucl Med · 2023-05-18

研究建立DOTA和MACROPA螯合剂与134Ce/134La的高效放射性标记方法,并在健康小鼠和22Rv1荷瘤雄性nu/nu小鼠中评估134Ce-PSMA-617和134Ce-MACROPA-PEG4-YS5的体内药代动力学。结果显示134Ce/134La标记物与相应225Ac缀合物的生物分布一致,提示134Ce/134La对可能作为225Ac放射配体治疗的PET成像替代物。

要点

  • 134Ce-MACROPA.NH2在室温1:1配体金属比下近定量标记,DOTA需10:1配体金属比和升温。
  • 134Ce/225Ac-DOTA/MACROPA.NH2缀合物快速经尿排泄、肝骨摄取低,证实高体内稳定性。
  • 134Ce-PSMA-617和134Ce-MACROPA-PEG4-YS5在22Rv1荷瘤小鼠中显示肿瘤摄取。

核心结论

  • 结果证明134Ce/134La标记的小分子和抗体药物具有PET成像潜力。
  • 225Ac与134Ce/134La相似的化学和药代动力学特征提示该对可能作为225Ac放射配体治疗的PET成像替代物。

研究设计与样本

  • 采用DOTA和MACROPA螯合剂在NH4OAc pH 8.0室温下与134Ce/134La混合进行放射性标记,并用放射性薄层色谱监测放射化学产率。
  • 在健康C57BL/6小鼠中通过动态小动物PET/CT成像和离体生物分布研究1小时内134Ce-DOTA/MACROPA.NH2复合物的体内分布,并与游离134CeCl3比较。
  • 在22Rv1荷瘤雄性nu/nu小鼠中进行134Ce-PSMA-617和134Ce-MACROPA-PEG4-YS5的临床前成像,并对134Ce/225Ac-MACROPA-PEG4-YS5缀合物进行离体生物分布。

主要发现

  • 134Ce-MACROPA.NH2在室温1:1配体金属比下显示近定量标记,而DOTA需要10:1配体金属比和升高温度。
  • 134Ce/225Ac-DOTA/MACROPA.NH2缀合物较游离134CeCl3显示快速尿排泄和低肝骨摄取,证实高体内稳定性。
  • 放射性薄层色谱和反相高效液相色谱证实,在标记肿瘤靶向载体PSMA-617和MACROPA-PEG4-YS5时,子体134La在母体134Ce衰变后从螯合物中排出。
  • 134Ce-PSMA-617和134Ce-MACROPA-PEG4-YS5两种缀合物在22Rv1荷瘤小鼠中均显示肿瘤摄取。
  • 134Ce-MACROPA.NH2、134Ce-DOTA和134Ce-MACROPA-PEG4-YS5的离体生物分布与相应225Ac缀合物吻合良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

225Ac-targeted α-radiotherapy is a promising approach to treating malignancies, including prostate cancer. However, α-emitting isotopes are difficult to image because of low administered activities and a low fraction of suitable γ-emissions. The in vivo generator 134Ce/134La has been proposed as a potential PET imaging surrogate for the therapeutic nuclides 225Ac and 227Th. In this report, we detail efficient radiolabeling methods using the 225Ac-chelators DOTA and MACROPA. These methods were applied to radiolabeling of prostate cancer imaging agents, including PSMA-617 and MACROPA-PEG4-YS5, for evaluation of their in vivo pharmacokinetic characteristics and comparison to the corresponding 225Ac analogs. Methods: Radiolabeling was performed by mixing DOTA/MACROPA chelates with 134Ce/134La in NH4OAc, pH 8.0, at room temperature, and radiochemical yields were monitored by radio-thin-layer chromatography. In vivo biodistributions of 134Ce-DOTA/MACROPA.NH2 complexes were assayed through dynamic small-animal PET/CT imaging and ex vivo biodistribution studies over 1 h in healthy C57BL/6 mice, compared with free 134CeCl3 In vivo, preclinical imaging of 134Ce-PSMA-617 and 134Ce-MACROPA-PEG4-YS5 was performed on 22Rv1 tumor-bearing male nu/nu-mice. Ex vivo biodistribution was performed for 134Ce/225Ac-MACROPA-PEG4-YS5 conjugates. Results: 134Ce-MACROPA.NH2 demonstrated near-quantitative labeling with 1:1 ligand-to-metal ratios at room temperature, whereas a 10:1 ligand-to-metal ratio and elevated temperatures were required for DOTA. Rapid urinary excretion and low liver and bone uptake were seen for 134Ce/225Ac-DOTA/MACROPA. NH2 conjugates in comparison to free 134CeCl3 confirmed high in vivo stability. An interesting observation during the radiolabeling of tumor-targeting vectors PSMA-617 and MACROPA-PEG4-YS5-that the daughter 134La was expelled from the chelate after the decay of parent 134Ce-was confirmed through radio-thin-layer chromatography and reverse-phase high-performance liquid chromatography. Both conjugates, 134Ce-PSMA-617 and 134Ce-MACROPA-PEG4-YS5, displayed tumor uptake in 22Rv1 tumor-bearing mice. The ex vivo biodistribution of 134Ce-MACROPA.NH2, 134Ce-DOTA and 134Ce-MACROPA-PEG4-YS5 corroborated well with the respective 225Ac-conjugates. Conclusion: These results demonstrate the PET imaging potential for 134Ce/134La-labeled small-molecule and antibody agents. The similar 225Ac and 134Ce/134La-chemical and pharmacokinetic characteristics suggest that the 134Ce/134La pair may act as a PET imaging surrogate for 225Ac-based radioligand therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bobba KN, Bidkar AP, Meher N, et al. Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac α-Radiotherapeutics. J Nucl Med. 2023. PMID: 37201957. doi:10.2967/jnumed.122.265355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。